Formulation of intravenous Carbamazepine emulsions by SolEmuls® technology

被引:40
作者
Akkar, A [1 ]
Müller, RH [1 ]
机构
[1] Free Univ Berlin, Dept Pharmaceut Biopharmaceut & Biotechnol, D-12169 Berlin, Germany
关键词
carbamazepine; emulsions; poorly soluble drugs; stability; particle size;
D O I
10.1016/S0939-6411(03)00028-6
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Oil in water (O/W) emulsions for parenteral nutrition can be employed as intravenous (i.v.) carriers for drugs that are poorly soluble in water and in oil by localising the drug in the interfacial lecithin layer, e.g. Amphotericin B emulsions. By now, the emulsion production required organic solvents. SolEmuls technology localises the drug in the interfacial layer by a solvent-free high-pressure homogenisation process. SolEmuls was applied to produce Carbamazepine emulsions at increasing drug concentrations from 0.5 to 10 mg/ml. Drug powder and Lipofundin emulsion were mixed and homogenised at 1500 bar. Characterisation of emulsions and short-term stability were performed by photon correlation spectroscopy (PCS) and laser diffractometry. Drug incorporation (absence of non-dissolved drug crystals) was investigated by light microscopy and a centrifugation test. The emulsions were physically stable and complete drug dissolution is possible up to 3 mg/ml. Up to 10 mg/ml drug hybrid dispersions of emulsion droplets and ultrafine nanocrystals were obtained. Both, emulsions and hybrid dispersions are suitable as i.v. injectables regarding size and stability. (C) 2003 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:305 / 312
页数:8
相关论文
共 15 条
[1]  
AKKAR A, 2003, UNPUB POORLY SOLUBLE
[2]  
BUTTLE I, 2002, 4 WORLD M PHARM BIOP, P1535
[3]  
BUTTLE L, THESIS FREE U BERLIN
[4]   EFFICACY AND TOLERANCE OF AN AMPHOTERICIN-B LIPID (INTRALIPID) EMULSION IN THE TREATMENT OF CANDIDAEMIA IN NEUTROPENIC PATIENTS [J].
CAILLOT, D ;
CASASNOVAS, O ;
SOLARY, E ;
CHAVANET, P ;
BONNOTTE, B ;
RENY, G ;
ENTEZAM, F ;
LOPEZ, J ;
BONNIN, A ;
GUY, H .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1993, 31 (01) :161-169
[5]  
DAVIS SS, 1988, Patent No. 0296845
[6]  
DINNENDAHL V, 1996, ARZNEISTOFF PROFILE, P1
[7]   Lipid-based amphotericin B: a review of the last 10 years of use [J].
Hann, IM ;
Prentice, HG .
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2001, 17 (03) :161-169
[8]   AN EMULSION FORMULATION OF AMPHOTERICIN-B IMPROVES THE THERAPEUTIC INDEX WHEN TREATING SYSTEMIC MURINE CANDIDIASIS [J].
KIRSH, R ;
GOLDSTEIN, R ;
TARLOFF, J ;
PARRIS, D ;
HOOK, J ;
HANNA, N ;
BUGELSKI, P ;
POSTE, G .
JOURNAL OF INFECTIOUS DISEASES, 1988, 158 (05) :1065-1070
[9]   STRUCTURE AND TOXICITY OF AMPHOTERICIN B/TRIGLYCERIDE EMULSION FORMULATIONS [J].
LANCE, MR ;
WASHINGTON, C ;
DAVIS, SS .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1995, 36 (01) :119-128
[10]   FAT EMULSIONS FOR PARENTERAL-NUTRITION .1. EVALUATION OF MICROSCOPIC AND LASER-LIGHT SCATTERING METHODS FOR THE DETERMINATION OF THE PHYSICAL STABILITY [J].
MULLER, RH ;
HEINEMANN, S .
CLINICAL NUTRITION, 1992, 11 (04) :223-236